Differences in the Biomarker Profile of De Novo Acute Heart Failure versus Decompensation of Chronic Heart Failure
The perception of acute heart failure (AHF) as a single entity is increasingly outdated, as distinct patient profiles can be discerned. Key heart failure (HF) studies have previously highlighted the difference in both the course and prognosis of de novo AHF and acute decompensated chronic HF (ADHF)....
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-11-01
|
| Series: | Biomolecules |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2218-273X/11/11/1701 |
| _version_ | 1827677175281614848 |
|---|---|
| author | Sylwia Nawrocka-Millward Jan Biegus Magdalena Hurkacz Mateusz Guzik Marta Rosiek-Biegus Ewa Anita Jankowska Piotr Ponikowski Robert Zymliński |
| author_facet | Sylwia Nawrocka-Millward Jan Biegus Magdalena Hurkacz Mateusz Guzik Marta Rosiek-Biegus Ewa Anita Jankowska Piotr Ponikowski Robert Zymliński |
| author_sort | Sylwia Nawrocka-Millward |
| collection | DOAJ |
| description | The perception of acute heart failure (AHF) as a single entity is increasingly outdated, as distinct patient profiles can be discerned. Key heart failure (HF) studies have previously highlighted the difference in both the course and prognosis of de novo AHF and acute decompensated chronic HF (ADHF). Accordingly, distinct AHF profiles with differing underlying pathophysiologies of disease progression can be shown. We compared a range of selected biomarkers in order to better describe the profile of de novo AHF and ADHF, including the inter alia—serum lactate, bilirubin, matrix metallopeptidase 9 (MMP-9), follistatin, intercellular adhesion molecule 1 (ICAM-1), lipocalin and galectin-3. The study comprised 248 AHF patients (de novo = 104), who were followed up for one year. The biomarker data of the de novo AHF and ADHF profiles was then compared in order to link biomarkers to their prognosis. Our study demonstrated that, although there are similarities between each patient profile, key biomarker differences do exist—predominantly in terms of NTproBNP, serum lactate, bilirubin, ICAM-1, follistatin, ferritin and sTfR (soluble transferrin receptor). ADHF tended to have compromised organ function and higher risks of both one-year mortality and composite endpoint (one-year mortality or rehospitalization for heart failure) hazard ratios (HR) (95% CI): 3.4 (1.8–6.3) and 2.8 (1.6–4.6), respectively, both <i>p</i> < 0.0001. Among the biomarkers of interest: sTfR HR (95% CI): 1.4 (1.04–1.8), NGAL<sub>(log)</sub> (neutrophil gelatinase-associated lipocalin) HR (95% CI): 2.0 (1.3–3.1) and GDF-15<sub>(log)</sub> (growth/differentiation factor-15) HR (95% CI): 4.0 (1.2–13.0) significantly impacted the one-year survival, all <i>p</i> < 0.05. |
| first_indexed | 2024-03-10T05:40:25Z |
| format | Article |
| id | doaj.art-920fb990e9ae42aabb5cdbfb26c9ff32 |
| institution | Directory Open Access Journal |
| issn | 2218-273X |
| language | English |
| last_indexed | 2024-03-10T05:40:25Z |
| publishDate | 2021-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomolecules |
| spelling | doaj.art-920fb990e9ae42aabb5cdbfb26c9ff322023-11-22T22:35:06ZengMDPI AGBiomolecules2218-273X2021-11-011111170110.3390/biom11111701Differences in the Biomarker Profile of De Novo Acute Heart Failure versus Decompensation of Chronic Heart FailureSylwia Nawrocka-Millward0Jan Biegus1Magdalena Hurkacz2Mateusz Guzik3Marta Rosiek-Biegus4Ewa Anita Jankowska5Piotr Ponikowski6Robert Zymliński7Institute of Heart Diseases, University Hospital, 50-556 Wroclaw, PolandInstitute of Heart Diseases, University Hospital, 50-556 Wroclaw, PolandDepartment of Clinical Pharmacology, Medical University, 50-556 Wroclaw, PolandInstitute of Heart Diseases, University Hospital, 50-556 Wroclaw, PolandDepartment of Internal Medicine, Pneumology and Allergology, Medical University, 50-369 Wroclaw, PolandInstitute of Heart Diseases, University Hospital, 50-556 Wroclaw, PolandInstitute of Heart Diseases, University Hospital, 50-556 Wroclaw, PolandInstitute of Heart Diseases, University Hospital, 50-556 Wroclaw, PolandThe perception of acute heart failure (AHF) as a single entity is increasingly outdated, as distinct patient profiles can be discerned. Key heart failure (HF) studies have previously highlighted the difference in both the course and prognosis of de novo AHF and acute decompensated chronic HF (ADHF). Accordingly, distinct AHF profiles with differing underlying pathophysiologies of disease progression can be shown. We compared a range of selected biomarkers in order to better describe the profile of de novo AHF and ADHF, including the inter alia—serum lactate, bilirubin, matrix metallopeptidase 9 (MMP-9), follistatin, intercellular adhesion molecule 1 (ICAM-1), lipocalin and galectin-3. The study comprised 248 AHF patients (de novo = 104), who were followed up for one year. The biomarker data of the de novo AHF and ADHF profiles was then compared in order to link biomarkers to their prognosis. Our study demonstrated that, although there are similarities between each patient profile, key biomarker differences do exist—predominantly in terms of NTproBNP, serum lactate, bilirubin, ICAM-1, follistatin, ferritin and sTfR (soluble transferrin receptor). ADHF tended to have compromised organ function and higher risks of both one-year mortality and composite endpoint (one-year mortality or rehospitalization for heart failure) hazard ratios (HR) (95% CI): 3.4 (1.8–6.3) and 2.8 (1.6–4.6), respectively, both <i>p</i> < 0.0001. Among the biomarkers of interest: sTfR HR (95% CI): 1.4 (1.04–1.8), NGAL<sub>(log)</sub> (neutrophil gelatinase-associated lipocalin) HR (95% CI): 2.0 (1.3–3.1) and GDF-15<sub>(log)</sub> (growth/differentiation factor-15) HR (95% CI): 4.0 (1.2–13.0) significantly impacted the one-year survival, all <i>p</i> < 0.05.https://www.mdpi.com/2218-273X/11/11/1701de novo AHFacute decompensated chronic HFheart failurebiomarkers |
| spellingShingle | Sylwia Nawrocka-Millward Jan Biegus Magdalena Hurkacz Mateusz Guzik Marta Rosiek-Biegus Ewa Anita Jankowska Piotr Ponikowski Robert Zymliński Differences in the Biomarker Profile of De Novo Acute Heart Failure versus Decompensation of Chronic Heart Failure Biomolecules de novo AHF acute decompensated chronic HF heart failure biomarkers |
| title | Differences in the Biomarker Profile of De Novo Acute Heart Failure versus Decompensation of Chronic Heart Failure |
| title_full | Differences in the Biomarker Profile of De Novo Acute Heart Failure versus Decompensation of Chronic Heart Failure |
| title_fullStr | Differences in the Biomarker Profile of De Novo Acute Heart Failure versus Decompensation of Chronic Heart Failure |
| title_full_unstemmed | Differences in the Biomarker Profile of De Novo Acute Heart Failure versus Decompensation of Chronic Heart Failure |
| title_short | Differences in the Biomarker Profile of De Novo Acute Heart Failure versus Decompensation of Chronic Heart Failure |
| title_sort | differences in the biomarker profile of de novo acute heart failure versus decompensation of chronic heart failure |
| topic | de novo AHF acute decompensated chronic HF heart failure biomarkers |
| url | https://www.mdpi.com/2218-273X/11/11/1701 |
| work_keys_str_mv | AT sylwianawrockamillward differencesinthebiomarkerprofileofdenovoacuteheartfailureversusdecompensationofchronicheartfailure AT janbiegus differencesinthebiomarkerprofileofdenovoacuteheartfailureversusdecompensationofchronicheartfailure AT magdalenahurkacz differencesinthebiomarkerprofileofdenovoacuteheartfailureversusdecompensationofchronicheartfailure AT mateuszguzik differencesinthebiomarkerprofileofdenovoacuteheartfailureversusdecompensationofchronicheartfailure AT martarosiekbiegus differencesinthebiomarkerprofileofdenovoacuteheartfailureversusdecompensationofchronicheartfailure AT ewaanitajankowska differencesinthebiomarkerprofileofdenovoacuteheartfailureversusdecompensationofchronicheartfailure AT piotrponikowski differencesinthebiomarkerprofileofdenovoacuteheartfailureversusdecompensationofchronicheartfailure AT robertzymlinski differencesinthebiomarkerprofileofdenovoacuteheartfailureversusdecompensationofchronicheartfailure |